to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection
Not Applicable
- Conditions
- HELICOBACTER PYLORI INFECTIONS
- Interventions
- Drug: Bismuth amoxilillin potassium
- Registration Number
- NCT07142798
- Lead Sponsor
- Kaohsiung Medical University
- Brief Summary
To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Subjects infected with Helicobacter pylori.
Exclusion Criteria
- Those who are allergic to the drugs used in this research.
- Those who have had stomach surgery.
- Those with severe liver cirrhosis or uremia or malignant tumors.
- Women who are pregnant or breastfeeding. If you have drug allergies or pregnant women or breast-feeding women during the test period, you can withdraw from the test early.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Helicbpacyer pylori infection Bismuth amoxilillin potassium Helicbpacyer pylori infection
- Primary Outcome Measures
Name Time Method Eradicaton rate of Helicobacter pylori 6 weeks after finishing study drugs 13CUBT
- Secondary Outcome Measures
Name Time Method evaluate side effect 2days after taking medicine evaluate drugy side effect by Questionnaire
Trial Locations
- Locations (1)
Kaohsiung Medical University Hospital
🇨🇳Kaohsiung City, Taiwan
Kaohsiung Medical University Hospital🇨🇳Kaohsiung City, Taiwan